Amgen INC.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$215Mgeneral payments (2019-2025)

$4.6Mresearch payments (2019-2025)

275,035clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $40M

2020 $20M

2021 $25M

2022 $24M

2023 $26M

2024 $40M

2025 $39M

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Rheumatology $32M

Dermatology $19M

Cardiovascular Disease $18M

Neurology (Psychiatry & Neurology) $17M

Internal Medicine $15M

Family Medicine $13M

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

Clinician	Location	Specialty	General payments (2019-2025)
Brian Druker	Portland, OR	Hematology & Oncology	$1,707,463.28
R Williams	Durham, NC	Cardiovascular Disease	$1,463,449.60
Michael Mcclung	Portland, OR	Endocrinology, Diabetes & Metabolism	$1,240,762.64
Felicia Cosman	West Haverstraw, NY		$1,043,521.61
Eduardo Chini	Rochester, MN	Anesthesiology	$683,215.60
Lori Siegel	Bannockburn, IL	Rheumatology	$668,633.53
Nihar Desai	New Haven, CT	Cardiovascular Disease	$638,177.89
Andrea Singer	Washington, DC	Internal Medicine	$610,942.96
John Stone	Boston, MA	Rheumatology	$592,365.84
Peter Toth	Sterling, IL	Family Medicine	$539,164.65

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.